Latest On DermTech, Inc (DMTK):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-05 00:22 EST | News | DermTech GAAP EPS of -$1.02 misses by $0.11, revenue of $3.48M beats by $0.01M | N/A |  |
| 2023-05-05 00:22 EST | News | DermTech, Inc. (DMTK) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-03 23:05 EST | News | DermTech Q1 2023 Earnings Preview | N/A | |
| 2023-04-15 00:35 EST | News | DermTech: Intriguing Product, Tough Market - Pivotal Year Ahead! | N/A | |
| 2023-03-03 20:47 EST | News | DermTech stock dips as Q4 revenue falls, CEO to step down | N/A | |
About DermTech, Inc (DMTK):
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information se read more...rvices through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
General
- Name DermTech, Inc
- Symbol DMTK
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDiagnostics & Research
- Full Time Employees 114
- Last Split Factor1:2
- Last Split Date2019-08-30
- Fiscal Year EndDecember
- IPO Date2017-08-10
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.dermtech.com
Valuation
- Trailing PE 58.85
- Price/Sales (Trailing 12 Mt.) 163.53
- Price/Book (Most Recent Quarter) 25.67
- Enterprise Value Revenue 266.17
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.90
- Next Year EPS Estimate -$2.06
- Next Quarter EPS Estimate -$0.48
- Operating Margin -583%
- Return on Assets -49%
- Return on Equity -93%
- Revenue 5.89 million
- Earnings Per Share -$3.08
- Revenue Per Share $0.35
- Gross Profit -96000
- Quarterly Earnings Growth 33.5%
Highlights
- Market Capitalization 1.53 billion
- EBITDA -10288739
- Analyst Target Price $64.25
- Book Value Per Share $1.58
Share Statistics
- Shares Outstanding 28.76 million
- Shares Float 20.83 million
- % Held by Insiders 2357%
- % Held by Institutions 57.65%
- Shares Short 1.55 million
- Shares Short Prior Month 892249
- Short Ratio 0.97
- Short % of Float 8%
- Short % of Shares Outstanding 6%
Technicals
- 52 Week High $84.49
- 52 Week Low $8.7
- 50 Day Moving Average 59.23
- 200 Day Moving Average 27.85
Dividends
- Dividend Date 2019-08-30
- ExDividend Date N/A
- Dividend Yield 0%
DermTech, Inc (DMTK) Dividend Calendar:
DMTK's last dividend payment was made to shareholders on August 30, 2019.
DermTech, Inc (DMTK) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
DermTech, Inc (DMTK) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
DermTech, Inc (DMTK) Chart:
DermTech, Inc (DMTK) News:
Below you will find a list of latest news for DermTech, Inc (DMTK) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
DermTech, Inc (DMTK) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest DMTK Trades:
DermTech, Inc (DMTK) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | POS AM (Post-Effective amendments for registration statement) | |
| 2020-11-05 | POS AM (Post-Effective amendments for registration statement) | |
| 2020-10-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-18 | UPLOAD (SEC-generated letter) | |
| 2020-09-17 | 424B3 (Prospectus [Rule 424(b)(3)]) | |
| 2020-09-17 | EFFECT (Notice of Effectiveness) | |
| 2020-09-17 | EFFECT (Notice of Effectiveness) | |
| 2020-09-15 | CORRESP (Correspondence) | |
| 2020-09-15 | CORRESP (Correspondence) | |
| 2020-09-14 | UPLOAD (SEC-generated letter) | |
| 2020-09-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-10 | 8-K (Current report) | |
| 2020-09-10 | 424B3 (Prospectus [Rule 424(b)(3)]) | |
| 2020-09-10 | 424B3 (Prospectus [Rule 424(b)(3)]) | |
| 2020-09-08 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-09-08 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-08-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-14 | 8-K (Current report) | |
DermTech, Inc (DMTK) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of DermTech, Inc (DMTK). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2357%
Institutional Ownership: 5765%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-26 | Gary E. Jacobs | Director | Buy | 692.00 | 1.08 | 747.36 | 523,903.00 | |
| 2020-09-10 | Claudia Ibarra | Chief Operating Officer | Sell | 2,803.00 | 11.25 | 31,535.15 | 117,667.00 | |
| 2020-09-10 | Claudia Ibarra | Chief Operating Officer | Sell | 4,802.00 | 10.57 | 50,780.67 | 120,470.00 | |
| 2020-09-10 | Todd Michael Wood | Chief Commercial Officer | Sell | 495.00 | 11.25 | 5,569.00 | 165,627.00 | |
| 2020-09-10 | Todd Michael Wood | Chief Commercial Officer | Sell | 850.00 | 10.57 | 8,988.67 | 166,122.00 | |
| 2020-09-10 | John Dobak | Chief Executive Officer | Sell | 910.00 | 11.25 | 10,237.96 | 542,469.00 | |
| 2020-09-10 | John Dobak | Chief Executive Officer | Sell | 1,560.00 | 10.57 | 16,496.84 | 543,379.00 | |
| 2020-06-25 | John Dobak | Chief Executive Officer | Buy | 60,916.00 | 544,939.00 | | ||
| 2020-06-24 | Claudia Ibarra | Chief Operating Officer | Buy | 14,647.00 | 125,272.00 | | ||
| 2020-06-24 | Kevin M Sun | Chief Financial Officer | Buy | 19,947.00 | 151,979.00 | | ||
| 2020-06-24 | Todd Michael Wood | Chief Commercial Officer | Buy | 15,952.00 | 166,972.00 | | ||
| 2020-06-24 | Burkhard Jansen | Chief Medical Officer | Buy | 12,872.00 | 84,037.00 | | ||
| 2020-06-24 | Zuxu Yao | Chief Scientific Officer | Buy | 13,317.00 | 84,364.00 | | ||
| 2020-06-17 | Enrico Picozza | Director | Buy | 8,000.00 | 14,000.00 | | ||
| 2020-06-17 | Cynthia Collins | Director | Buy | 8,000.00 | 33,483.00 | | ||
| 2020-06-17 | HERM ROSENMAN | Director | Buy | 8,000.00 | 43,224.00 | | ||
| 2020-06-17 | Gary E. Jacobs | Director | Buy | 8,000.00 | 523,211.00 | | ||
| 2020-06-17 | SCOTT R PANCOAST | Director | Buy | 8,000.00 | 52,514.00 | | ||
| 2020-06-17 | Matthew L. Posard | Director | Buy | 8,000.00 | 52,965.00 | | ||
| 2020-04-29 | Matthew L. Posard | Director | Buy | 9,702.00 | 6.94 | 67,331.88 | 44,965.00 | |